Angelini finds Catalyst for its US growth ambitions with $4.1B buyout

With an eye on the lucrative U.S. market, Italy’s Angelini Pharma will acquire rare disease specialist Catalyst Pharmaceuticals and its potential blockbuster Firdapse for $4.1 billion.

By FiercePharma · May 8, 2026 · via FiercePharma

Angelini finds Catalyst for its US growth ambitions with $4.1B buyout

Image: FiercePharma

This is an aggregated industry headline. Read the full story at FiercePharma →

RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.